Pluri : Company deck – Q2 2026
PLUR
Published on 04/19/2026 at 06:18 am EDT
Q2 2026
Pluri Venture Creation
Company
Sectors
Partners
~$14 million
(as of December 31, 2025)
>
Regenerative Medicine and wellness
Cultivated Meat
Cell-Based
Agriculture
Eight Billion Lives. One Planet.
Zero Time to Waste.
Aging and Health Climate Change Food Security Sustainability
A growing, aging world urgently needs scalable, sustainable solutions
Human health and Longevity
Placental cell therapy
Injectable placental cell-based therapy designed to reduce inflammation and promote tissue healing
Longevity
Immunotherapy
Osteoarthritis - Full funding for PROTO consortium
Medical aesthetics
Breakthrough cellular technology for the next generation of skin therapies and regenerative medicine
- 100% ownership
Cultivated coffee 100% ownership
Cultivated cacao 79% ownership
Cell-based agriculture
Funded POC with ICL
Funded POC with global Agriculture Corp.
Cultivated meat 69% ownership
at a value of $62 million
Knowhow and expertise
Validated technology and robust IP
Deep market understanding and strong partnerships
Infrastructure and corporate services
GMP Compliance Declaration
Pluri Technological Platform
Cell-based innovations, powered by validated technology
Innovative
Patented 3D cell expansion
High-quality cells produced in large quantities
Versatile cell source and types
Compatible with human, animal, and plant cells
Modular production system
Reduces costs and minimizes ecological impact
Validated
Automated, scalable process
Efficient and fully controlled
GMP Compliance Declaration
Ensures quality and compliance with standards
Consistent batch production
Proven reliability from batch to batch
6
Pluri Technological Platform
Bio-Farming: Industrial Scale Production
Advantages
Low production costs
Significantly lower production costs compared to traditional methods
Maintaining high quality
Critical advantage in emerging industries such as cultured meat, coffee, cacao, etc.
Intelligent control system
Reduces the need for personal intervention, ensures consistency and quality
PluriMatrix
7
WHO
PLX Cells
PLX Exosomes &
Plant Extracellular Vesicles
Regenerative skin support, Antioxidant protection, Anti-inflammatory action, Wound-healing support, Collagen-boosting
("Dermatologically tested", "Clinically tested", "Safe for skin", "Kind to skin",
"Dermatologist Approved")
* Subgroup analysis of patients with baseline HbA1c levels below 6.5%
** annual mortality rate in PLX treated patient vs Center for International Blood and Marrow Transplant Research (CIBMTR) registry data
Florida law (SB 1768 / HB 1617) passed on July,2025
Market Opportunity
Science-Driven Innovation
$200B
From Therapy to Lifestyle
Partnership &
Growth Ingredients:
•
•
•
Pluri holds majority ownership in all companies in which it is a partner
Ever After Foods leverages Pluri's cell expansion technology to produce mass scale, cost-effective food products in an efficient and sustainable manner, aiming to solve the industry's scalability challenges
Environmental
Less land and water
are required
Fewer greenhouse gases
Less agriculture-related pollution
Ethical
Adheres to ethical animal welfare standards
Consumer
Natural flavor modification
Safe modification for healthier food and raw materials
Granted exclusive global royalty-bearing
license to use its IP and expertise
I $7.5 million according to a $40 million pre-money valuation
Expected completion of manufacturing system development, initiation of regulatory processes, and receipt of initial regulatory approvals in selected markets
Unstable supply
Complex supply chain
$11,000
Rising prices
risen
Drying
Roasting
Brewing
Inconsistent quality
3an.
2024
Internal POC
(funded by Pluri)
x •
Feb.
2024
May
2024
Company creation, CEO and team recruitment
May
2025
Sep. 2024
Product prototype
H2
2025
POC deals with global partners
H2
2025
2020
Completion of product POC with the Japanese partner
Progress to Regulatory submissions in the U.S. and Israel
2020
Company founded by Plantae Bioscience, The Kitchen
(a Strauss Group company), and Tal Govrin.
An investment of 2.5 million NIS was made for initial feasibility
Completion of acquisition by Pluri POC deals with
global partners
-79a/a ownership
Completion of development processes to scale up production volumes
Completion of all main elements for Regulatory submissions in the
U.S. and Israel
Regulatory Scientific Collaborations and Partnering
Funding
Yaky Yanay
CEO & President
Liat Zalts
Chief Financial Officer
Lior Raviv
Chief Technology Officer
Dr. Michal Sheleg, PhD
VP Clinical Development
Nimrod Bar Zvi
Chief Commercial Officer
Dr. Arthur Machlenkin, PhD
Chief Scientific Officer
Nofar Glaich-Dabach
VP Human Resources
Orly Amiran
Chief Quality Officer
Efrat Kaduri
Chief BD Officer - Pharma
Ori Shalem
VP Operations & Manufacturing
Our cell-based innovations are aimed at transforming industries with a goal to create a more sustainable, healthier world. From the food we eat to the medicine we consume, we are building solutions that can potentially serve humanity,
one breakthrough at a time.
For further info: [email protected]
Disclaimer
Pluri Inc. published this content on April 18, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 19, 2026 at 10:17 UTC.